Mechanisms of Immune-Related Complications in Cancer Patients Treated with Immune Checkpoint Inhibitors

被引：32

作者：

Konig, David ^{[1
]}

Laubli, Heinz ^{[1
,2
]}

机构：

[1] Univ Hosp Basel, Div Med Oncol, Petersgraben 4, CH-4031 Basel, Switzerland

[2] Univ Basel, Dept Biomed, Lab Canc Immunotherapy, Basel, Switzerland

来源：

PHARMACOLOGY | 2021年 / 106卷 / 3-4期

关键词：

Cytotoxic T-lymphocyte-associated antigen 4; Programmed cell death protein-1; T cell; B cell; Antibody; Autoimmune; Cytokine; Cross-presentation;

D O I：

10.1159/000509081

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Immune checkpoint inhibitors (ICIs) have changed the prognosis of many cancer patients. Blocking antibodies targeting inhibitory cytotoxic T-lymphocyte-associated antigen 4 or programmed cell death protein-1 receptors or the programmed cell death ligand-1 have led to long-lasting remissions in patients with even advanced cancers. Main side effects induced by ICIs are inflammatory complications with sometimes severe sequelae for patients. Recent studies have improved our understanding how such immune-related adverse events (irAEs) develop. Here, we summarize the current knowledge of pathomechanisms involved in the de-velopment of irAEs with a particular focus on potential pathways that could be targeted to prevent severe immune-related complications in patients treated with cancer immunotherapy.

引用

页码：123 / 136

页数：14

共 125 条

[1] Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis [J].

Abu-Sbeih, Hamzah ;

Ali, Faisal S. ;

Naqash, Abdul Rafeh ;

Owen, Dwight H. ;

Patel, Sandipkumar ;

Otterson, Gregory A. ;

Kendra, Kari ;

Ricciuti, Biagio ;

Chiari, Rita ;

De Giglio, Andrea ;

Sleiman, Joseph ;

Funchain, Pauline ;

Wills, Beatriz ;

Zhang, Jiajia ;

Naidoo, Jarushka ;

Philpott, Jessica ;

Gao, Jianjun ;

Subudhi, Sumit K. ;

Wang, Yinghong .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (30) :2738-+

[2] Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis [J].

Abu-Sbeih, Hamzah ;

Ali, Faisal S. ;

Luo, Wenyi ;

Qiao, Wei ;

Raju, Gottumukkala S. ;

Wang, Yinghong .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6

[3] Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells<bold> </bold> [J].

Anderson, Ronald ;

Theron, Annette J. ;

Rapoport, Bernardo L. .

FRONTIERS IN IMMUNOLOGY, 2019, 10

[4] Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Kurata, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

Carpeno, J. de Castro ;

Faivre-Finn, C. ;

Reck, M. ;

Vansteenkiste, J. ;

Spigel, D. R. ;

Wadsworth, C. ;

Melillo, G. ;

Taboada, M. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (24) :2342-2350

[5] Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens A Systematic Review and Meta-analysis [J].

Barroso-Sousa, Romualdo ;

Barry, William T. ;

Garrido-Castro, Ana C. ;

Hodi, F. Stephen ;

Min, Le ;

Krop, Ian E. ;

Tolaney, Sara M. .

JAMA ONCOLOGY, 2018, 4 (02) :173-182

[6] The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3 [J].

Bennett, CL ;

Christie, J ;

Ramsdell, F ;

Brunkow, ME ;

Ferguson, PJ ;

Whitesell, L ;

Kelly, TE ;

Saulsbury, FT ;

Chance, PF ;

Ochs, HD .

NATURE GENETICS, 2001, 27 (01) :20-21

[7] Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer [J].

Berner, Fiamma ;

Bomze, David ;

Diem, Stefan ;

Ali, Omar Hasan ;

Faessler, Mirjam ;

Ring, Sandra ;

Niederer, Rebekka ;

Ackermann, Christoph J. ;

Baumgaertner, Petra ;

Pikor, Natalia ;

Cruz, Cristina Gil ;

van de Veen, Willem ;

Akdis, Muebeccel ;

Nikolaev, Sergey ;

Laeubli, Heinz ;

Zippelius, Alfred ;

Hartmann, Fabienne ;

Cheng, Hung-Wei ;

Hoenger, Gideon ;

Recher, Mike ;

Goldman, Jonathan ;

Cozzi, Antonio ;

Fruek, Martin ;

Neefjes, Jacques ;

Driessen, Christoph ;

Ludewig, Burkhard ;

Hegazy, Ahmed N. ;

Jochum, Wolfram ;

Speiser, Daniel E. ;

Flatz, Lukas .

JAMA ONCOLOGY, 2019, 5 (07) :1043-1047

[8] Role of Human Leukocyte Antigens (HLA) in Autoimmune Diseases [J].

Bodis, Gergely ;

Toth, Victoria ;

Schwarting, Andreas .

RHEUMATOLOGY AND THERAPY, 2018, 5 (01) :5-20

[9] Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline [J].

Brahmer, Julie R. ;

Lacchetti, Christina ;

Schneider, Bryan J. ;

Atkins, Michael B. ;

Brassil, Kelly J. ;

Caterino, Jeffrey M. ;

Chau, Ian ;

Ernstoff, Marc S. ;

Gardner, Jennifer M. ;

Ginex, Pamela ;

Hallmeyer, Sigrun ;

Chakrabarty, Jennifer Holter ;

Leighl, Natasha B. ;

Mammen, Jennifer S. ;

McDermott, David F. ;

Naing, Aung ;

Nastoupil, Loretta J. ;

Phillips, Tanyanika ;

Porter, Laura D. ;

Puzanov, Igor ;

Reichner, Cristina A. ;

Santomasso, Bianca D. ;

Seigel, Carole ;

Spira, Alexander ;

Suarez-Almazor, Maria E. ;

Wang, Yinghong ;

Weber, Jeffrey S. ;

Wolchok, Jedd D. ;

Thompson, John A. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) :1714-+

[10] CTLA-4 and PD-1 Control of T-Cell Motility and Migration: Implications for Tumor Immunotherapy [J].

Brunner-Weinzierl, Monika C. ;

Rudd, Christopher E. .

FRONTIERS IN IMMUNOLOGY, 2018, 9

← 1 2 3 4 5 6 7 8 9 10 →